China Medical Insurance, Health Reforms Lure Sanofi, BMS, Other MNCs
This article was originally published in PharmAsia News
Executive Summary
China's recent decision to broaden its medical-insurance coverage and invest more in chronic diseases has opened the floodgates for foreign drug makers, particularly those with Type 2 diabetes drugs.